# Forbion

Forbion is a Private Equity based in Naarden, Netherlands.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Naarden, Netherlands
- **Region:** Europe
- **Address:** Gooimeer 2-35, 1411 DC Naarden, The Netherlands
- **Founded:** 2000
- **Assets under management:** Undisclosed
- **Website:** forbion.com
- **LinkedIn:** https://www.linkedin.com/company/forbion

## Regulatory record

- **CRD number:** 162925
- **SEC file number:** 802-76457
- **Registration status:** Registered
- **Reports private funds:** Yes
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/162925

## About

Forbion is a leading global venture capital firm with deep expertise in Europe. It invests in innovative biotech companies across multiple fund strategies covering all stages of (bio-)pharmaceutical drug development, and also invests via its BioEconomy strategy in sustainable solutions in food, agriculture, materials, and environmental technologies. The firm manages just over €5 billion across eleven funds and operates a joint venture with BGV for seed and early-stage investing.

## Sectors

- Biotechnology
- AgriTech & FoodTech
- Environmental Technologies

## Offices

- Munich, Germany
- Boston, MA, United States

## People

- Sander Slootweg — Managing Partner and Co-Founder
- Geert-Jan Mulder — Managing Partner and Co-Founder
- Bart Bergstein — General Partner

## Questions

### How does Forbion structure its investment platform?

Forbion operates five distinct strategies under one platform. Forbion Ventures targets pre-clinical and early clinical biotech companies; Forbion Growth provides private growth capital and crossover financing for clinical-stage drug developers; a joint venture with BioGeneration Ventures handles company formation and pre-seed activity; and Forbion BioEconomy runs a dedicated €200m fund for biotechnology applications in food, agriculture, materials and environmental technologies. The growth strategy also executes public-block trades, PIPEs and VPEs.

### What is the relationship between Forbion and BioGeneration Ventures?

Forbion runs a joint venture with BioGeneration Ventures, branded as the FIRST Fund, which operates as the early-stage strategy on the Forbion platform. The collaboration covers pre-creation, pre-seed and company formation stages, sitting alongside Forbion's own Ventures and Growth funds. This gives Forbion an origination pipeline that starts before conventional seed rounds.

### Does Forbion invest outside biotech?

Yes. The BioEconomy strategy targets companies that apply biotechnology to planetary-health challenges, organized across four sectors: food, agriculture, materials and environmental technologies. Portfolio-company Genomines, for example, uses plant-based methods to extract metals. This fund operates separately from the human-health venture and growth vehicles.

### What investment stages does Forbion cover?

Forbion covers the full company lifecycle. The BGV joint venture addresses pre-creation and pre-seed. Ventures funds back seed and early clinical rounds. Growth funds provide private capital for clinical-stage development and selectively write crossover and public-equity checks, including PIPE and block trades. BioEconomy funds participate from Series A onward.

### Where does Forbion deploy capital geographically?

Forbion invests in Europe and the United States, supported by offices in Naarden (Netherlands), Munich (Germany) and Boston (Massachusetts). The transatlantic presence enables local access to both European and US biotech clusters.

### How much capital has Forbion raised?

The firm reports €5bn deployed across 11 funds. Recent vehicles include Forbion Growth Opportunities Fund III at €1.2bn, Forbion Ventures VII at €890m, and the inaugural Forbion BioEconomy I at €200m. Forbion does not publish an aggregate AUM figure for all active funds.

### What is Forbion's approach to ESG and sustainability?

Forbion states that it integrates ESG principles into its human and planetary health investments, focusing on patient impact, societal benefits and sustainability. The firm's website frames the BioEconomy fund explicitly as a vehicle to leverage biotechnology for cleaning and feeding the planet.

## Related profiles

- [Forage Capital Partners](https://altss.com/profile/forage-capital-partners)
- [Force Over Mass Capital](https://altss.com/profile/force-over-mass-capital)

---

Last updated: 2026-08-11T15:06:49.768Z

Canonical page: https://altss.com/profile/forbion

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology